logo
  • SELECT LICENSE :

  • US $4,299.00
  • US $8,599.00

Small Molecule API Market, By Type (Biological API, Synthetic API), By Offering (Diabetes, Cardiovascular, Oncology, Immunological Disorders and Others) opportunities and forecast 2020-2027

  • DLR2137
  • 20 September, 2020
  • Pharma & Healthcare
  • Pages: 120
  • Global
Market Overview

Small molecule API is active ingredient used for the pharmaceutical development. It is extremely used for regulation of the biological processes. APIs are the combination of substances which may have direct effect on the diagnosis, treatment, prevention and mitigation of diseases. The molecules can be given orally and absorbed by body easily. They can easily reach to intracellular site of the action due to small size.

The global market has witnessed tectonic surge over past few years, largely due to growing demand for the small molecule drugs, new developments in pharmaceutical industry, and the entry of big CMO’s in the business. The sector is making great profits and is well armed with the developed infrastructure. The growth in pharmaceutical sector is further propelling the small molecule API global market. With the increasing incidences of the diseases and discovery of novel viruses are projected to impact growth of market positively. Furthermore, the increased incidence of cardiovascular diseases and cancer is projected to accelerate the rivalry among market players, thus encouraging the growth around the globe. The better adoption of generic drugs has further led to the affordable healthcare spending and has supplementary increased production of the small molecule APIs. These factors are projected to promote growth of market in the coming future.

Segment Overview

The growth of the pharmaceutical sector has been helpful to expansion of small molecule API market. Cardiovascular disorder section is anticipated to grow at highest CAGR during the forecast period due to improved consumer demand. The ease of obtaining of the raw materials has been beneficial to the development of industry further. Industry is anticipated to gain impetus with the expansion of better delivery networks that will speed up the industry growth during the forecast period.

Regional Overview

North America attains the maximum market share in global market and is expected to retain the share in foreseeable future. Market growth can be accredited to high availability of funds, growing prevalence of cancer, well-developed healthcare sector, and rising clinical trials.
Europe bags second spot in global market and is projected to exhibit strong growth in coming years, mainly owing to initiatives undertaken by governments to support growth of pharmaceutical sector. The high obtainability of funds and increased adoption of the next-generation healthcare expertise are further projected to favour the growth of small molecule API market.

Competitor overview

The business strategy of competitors in market is based currently on exploiting the dynamic pace of the technological innovations that have led to the plenty of changes both in the terms of handling competition and product development. The particular trend has permitted portfolio development along with affinity for modification in sector that has indirectly enabled players to use valuable state of dealings accessible in this industry. Use of these projections by candidates, who are trying to promote their industry stake by the intensive expansion can inspire the expansion of industry. The companies are trying to capture and create financial funds in an appropriate manner. This has raised the potential for forthcoming growth period considerably. The planned decision-making process has augmented the productivity of the companies so that the companies maintain their liquidity and sustain possible to take active choices in terms of the strategy designing and employment.

Key Players
  1. Allergan Plc,
  2. Aurobindo Pharma,
  3. Albemarle Corporation,
  4. Dr. Reddy's Laboratories Ltd,
  5. Glaxosmithkline Plc,
  6. Cambrex Corporation,
  7. Lonza,
  8. Merck Sharp & Dohme Corp.,
  9. Mylan N.V.
  10. Novartis AG

Market Segmentation
By Type
  • Biological API
  • Synthetic/Chemical API
By Application
  • Oncology
  • Immunological Disorders
  • Cardiovascular
  • Diabetes
  • Others
By Geography
  • North America
    • US
    • Canada
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • UAE
    • Rest of LAMEA


1 INTRODUCTION 11

  • 1.1 DEFINITION 11
  • 1.2 SCOPE OF STUDY 11
    • 1.2.1 RESEARCH OBJECTIVE 11
    • 1.2.2 ASSUMPTIONS & LIMITATIONS 12
      • 1.2.2.1 ASSUMPTIONS 12
      • 1.2.2.2 LIMITATIONS 12
  • 1.3 MARKET STRUCTURE: 12
  • 2 RESEARCH METHODOLOGY 13

    • 2.1 RESEARCH PROCESS: 13
    • 2.2 PRIMARY RESEARCH 14
    • 2.3 SECONDARY RESEARCH: 14

    3 MARKET DYNAMICS 15

    • 3.1 DRIVERS 15
      • 3.1.1 GROWING DEMAND FOR NEWLY DEVELOPED SMALL MOLECULES DRUGS 15
      • 3.1.2 GROWING TREND OF OUTSOURCING 15
      • 3.1.3 GROWING PHARMACEUTICAL INDUSTRY IN DEVELOPING NATIONS 16
    • 3.2 RESTRAINTS 16
      • 3.2.1 AUSTERITY MEASURES IN EUROPE 16
    • 3.3 OPPORTUNITIES 16
    • 3.4 MACROECONOMIC INDICATORS 17

    4 MARKET FACTOR ANALYSIS 18

    • 4.1 PORTERS FIVE FORCES MODEL 18
    • 4.2 BARGAINING POWER OF SUPPLIERS 19
    • 4.3 BARGAINING POWER OF BUYERS 19
    • 4.4 THREAT OF NEW ENTRANTS 19
    • 4.5 THREAT OF SUBSTITUTES 19
    • 4.6 INTENSITY OF RIVALRY 19

    5 GLOBAL SMALL MOLECULE API MARKET, BY TYPE 20

    • 5.1 SYNTHETIC/CHEMICAL API 21
    • 5.2 BIOLOGICAL API 22

    6 GLOBAL SMALL MOLECULE API MARKET, BY APPLICATION 24

    • 6.1 CARDIOVASCULAR 26
    • 6.2 ONCOLOGY 27
    • 6.3 DIABETES 28
    • 6.4 IMMUNOLOGICAL DISORDERS 29

    7 GLOBAL SMALL MOLECULE API MARKET, BY MANUFACTURING METHODS 30

    • 7.1 IN-HOUSE MANUFACTURING 32
    • 7.2 CONTRACT MANUFACTURING 33
      • 7.2.1 INTRODUCTION 33

    8 GLOBAL SMALL MOLECULE API MARKET, BY REGION 36

    • 8.1 NORTH AMERICA 38
      • 8.1.1 INTRODUCTION 38
    • 8.2 EUROPE 45
      • 8.2.1 INTRODUCTION 45
    • 8.3 ASIA-PACIFIC 57
      • 8.3.1 INTRODUCTION 57
    • 8.4 MIDDLE EAST & AFRICA 71
      • 8.4.1 INTRODUCTION 71

    9 COMPETITIVE LANDSCAPE 76

    • 9.1 MAJOR STRATEGIES ADOPTED BY MARKET PLAYERS 76
      • 9.1.1 STRATEGIC PARTNERSHIP 77
      • 9.1.2 MERGER & ACQUISITION 77

    10 COMPANY PROFILE 79

    • 10.1 ALBEMARLE CORPORATION 79
      • 10.1.1 OVERVIEW 79
      • 10.1.2 PRODUCT OVERVIEW 79
      • 10.1.3 FINANCIALS 80
      • 10.1.4 KEY DEVELOPMENTS 80
    • 10.2 ALLERGAN PLC 81
      • 10.2.1 OVERVIEW 81
      • 10.2.2 PRODUCT OVERVIEW 81
      • 10.2.3 FINANCIALS 82
      • 10.2.4 KEY DEVELOPMENTS 82
    • 10.3 AUROBINDO PHARMA 83
      • 10.3.1 OVERVIEW 83
      • 10.3.2 PRODUCT OVERVIEW 83
      • 10.3.3 FINANCIALS 84
      • 10.3.4 STRATEGY 84
      • 10.3.5 KEY DEVELOPMENT 84
    • 10.4 CAMBREX CORPORATION 85
      • 10.4.1 OVERVIEW 85
      • 10.4.2 PRODUCT OVERVIEW 85
      • 10.4.3 FINANCIALS 86
      • 10.4.4 KEY DEVELOPMENTS 86
    • 10.5 DR. REDDY’S LABORATORIES LTD. 87
      • 10.5.1 OVERVIEW 87
      • 10.5.2 PRODUCT OVERVIEW 87
      • 10.5.3 FINANCIALS 88
      • 10.5.4 KEY DEVELOPMENTS 88
    • 10.6 GLAXOSMITHKLINE PLC 89
      • 10.6.1 OVERVIEW 89
      • 10.6.2 PRODUCT OVERVIEW 89
      • 10.6.3 FINANCIALS 90
      • 10.6.4 STRATEGY 90
      • 10.6.5 KEY DEVELOPMENTS 91
    • 10.7 LONZA 91
      • 10.7.1 OVERVIEW 91
      • 10.7.2 PRODUCT OVERVIEW 91
      • 10.7.3 FINANCIALS 92
      • 10.7.4 STRATEGY 92
      • 10.7.5 KEY DEVELOPMENTS 93
    • 10.8 MERCK SHARP & DOHME CORP. 93
      • 10.8.1 OVERVIEW 93
      • 10.8.2 PRODUCT OVERVIEW 94
      • 10.8.3 FINANCIAL 94
      • 10.8.4 KEY DEVELOPMENTS 95
    • 10.9 MYLAN N.V. 95
      • 10.9.1 OVERVIEW 95
      • 10.9.2 PRODUCT OVERVIEW 96
      • 10.9.3 FINANCIALS 96
      • 10.9.4 KEY DEVELOPMENTS 97
    • 10.10 NOVARTIS AG 97
      • 10.10.1 OVERVIEW 97
      • 10.10.2 PRODUCT OVERVIEW 98
      • 10.10.3 FINANCIALS 98
      • 10.10.4 STRATEGY 98
      • 10.10.5 DEVELOPMENTS 99
    • 10.11 PFIZER INC. 99
      • 10.11.1 OVERVIEW 99
      • 10.11.2 PRODUCT OVERVIEW 100
      • 10.11.3 FINANCIALS 100
      • 10.11.4 KEY DEVELOPMENTS 101
    • 10.12 SIEGFRIED AG 101
      • 10.12.1 OVERVIEW 101
      • 10.12.2 PRODUCT OVERVIEW 101
      • 10.12.3 FINANCIALS 102
      • 10.12.4 KEY DEVELOPMENTS 102
    • 10.13 SUN PHARMACEUTICAL INDUSTRIES LTD. 103
      • 10.13.1 OVERVIEW 103
      • 10.13.2 PRODUCT OVERVIEW 103
      • 10.13.3 FINANCIALS 104
      • 10.13.4 KEY DEVELOPMENTS 104
    • 10.14 TEVA PHARMACEUTICAL INDUSTRIES LTD 105
      • 10.14.1 OVERVIEW 105
      • 10.14.2 PRODUCT OVERVIEW 105
      • 10.14.3 FINANCIALS 106
      • 10.14.4 STRATEGY 106
      • 10.14.5 KEY DEVELOPMENTS 107

    Report You Might be Interested